(Total Views: 345)
Posted On: 06/24/2021 1:49:18 PM
Post# of 36564
Both websites , GNBT/NGIO, are a great way to communicate and keep shareholders up to date without releasing PR's. According to the latest Q it appears NGIO will receive ALL vaccine revenue. Initially 20M of the first 100M, I believe EPIVAX will also receive 20% of all vaccine (NGIO) revenue. Any target estimate to list GNBT??? ANY analyst/institutional interest?? LISTING has been a priority since day one ???
Another reason why the pps continues to go lower:........
a. Offer Generex 20% of the equity interests in the Joint Entity; NGIO (imo class
shall be the 100% owner of any equity consideration provided to Generex pursuant to the February 19, 2021 "Work, Cost and Fee Sharing Agreement," disclosed below; or b. Cash payments to Generex in a price equal to $2 per dose for the COVID-19 vaccine of which, Generex shall pay NGIO 90% of all fees derived from the COVID Agreement, as a result of using NGIO technology.
3. Equity Distributions: the net profits of the Joint Entity shall pay first to Generex until Generex receives $20 million, then the China Partners will receive the next $80 million in net profits from the Joint Entity and thereafter Generex and the China Partners will receive net profits from the Joint Entity in accordance with their pro rate equity interests.
Another reason why the pps continues to go lower:........
a. Offer Generex 20% of the equity interests in the Joint Entity; NGIO (imo class
shall be the 100% owner of any equity consideration provided to Generex pursuant to the February 19, 2021 "Work, Cost and Fee Sharing Agreement," disclosed below; or b. Cash payments to Generex in a price equal to $2 per dose for the COVID-19 vaccine of which, Generex shall pay NGIO 90% of all fees derived from the COVID Agreement, as a result of using NGIO technology. 3. Equity Distributions: the net profits of the Joint Entity shall pay first to Generex until Generex receives $20 million, then the China Partners will receive the next $80 million in net profits from the Joint Entity and thereafter Generex and the China Partners will receive net profits from the Joint Entity in accordance with their pro rate equity interests.
(0)
(0)
